US SEC Trading Suspension Halt Orders — October 30, 2026

30-10-2026

Alset Inc. received a Nasdaq notification letter on October 28, 2026, stating it no longer meets the $1.00 minimum bid price requirement under Rule 5550(a)(2) after its closing bid price stayed below $1.00 for 30 consecutive trading days. The notice has no immediate effect on listing; the company has until April 26, 2027 (180 calendar days) to regain compliance, potentially extendable by another 180 days if it meets market value and other initial listing standards. Alset intends to monitor its bid price and has previously announced a planned 1-for-5 reverse stock split, with timing expected to be announced imminently.

• · Notification received October 28, 2026; 8-K filed October 30, 2026
• · Deficiency is under Nasdaq Marketplace Rule 5550(a)(2) for The Nasdaq Capital Market
• · Compliance cure mechanism per Rule 5810(c)(3)(A)
• · To qualify for the second 180-day period, company must meet market value of publicly held shares and all other initial listing standards except bid price, and provide written notice of intent to cure, potentially via reverse stock split
• · If Staff determines the company cannot cure, securities would be subject to delisting, with a possible appeal but no assurance of continued listing
• · Company headquarters: 4800 Montgomery Lane, Suite 210, Bethesda, Maryland 20814
• · Commission File Number 001-39732; IRS EIN 83-1079861; incorporated in Texas

30-10-2026

Accendra Health, Inc. (formerly Owens & Minor, trading as ACH on NYSE) received a notice from the NYSE on October 27, 2026 that it is not in compliance with Section 802.01B, which requires an average market capitalization of at least $50.0 million over a consecutive 30 trading-day period and stockholders' equity of at least $50.0 million. The notice has no immediate impact on the listing, but the company must notify the NYSE within 10 business days of its intent to submit a business plan and submit that plan within 45 calendar days demonstrating how it will regain compliance within 18 months. The company says the notice does not affect its business operations or SEC reporting obligations.

• · Company name in filing is Accendra Health, Inc., with common stock trading under symbol ACH on the NYSE
• · Notice received October 27, 2026; press release issued October 30, 2026
• · If the NYSE accepts the business plan, the company will be subject to quarterly monitoring by the NYSE of progress against the plan
• · The notice has no immediate impact on the listing of the common stock, subject to compliance with other NYSE continued listing requirements
• · Company is incorporated in Virginia, IRS Employer Identification No. 54-1701843, Commission File Number 001-09810
• · Principal offices located at 4435 Waterfront Drive, Suite 300, Glen Allen, Virginia 23060

30-10-2026

Annovis Bio received a NYSE notice on October 29, 2026 that it no longer complies with Section 802.01B continued listing standards, as its 30 trading-day average market capitalization was approximately $48.4 million (below the $50 million threshold) while stockholders' equity was a deficit of approximately $(4.3) million as of June 30, 2026. The company has 45 days to submit a compliance plan and up to 9 months to cure the deficiency; the stock continues trading under 'ANVS' but with a '.BC' indicator denoting below-criteria status. The notice has no immediate impact on operations or SEC reporting obligations, though failure to submit or gain acceptance of the plan would trigger delisting proceedings.

• · NYSE generally views trading below $0.10 per share as 'abnormally low' and may take accelerated delisting action
• · NYSE will review the company on a semi-annual basis to confirm compliance with the plan
• · The '.BC' indicator will be removed once the company regains compliance
• · The notice does not conflict with or cause an event of default under any material debt or other agreements
• · Press release dated October 30, 2026 attached as Exhibit 99.1

30-10-2026

Cyngn Inc. notified Nasdaq on October 30, 2026 that, upon the resignation of director and Audit Committee Chair Karen Macleod, its Audit Committee will fall to two members, breaching Nasdaq Listing Rule 5605(c)(2)(A) requiring at least three members and one financially sophisticated member. The company expects until the earlier of its next annual meeting or November 3, 2027 to regain compliance and intends to appoint a qualified independent director. Macleod, who notified the company on October 26, 2026 of her decision not to stand for re-election at the November 3, 2026 Annual Meeting, stated her departure was not due to any disagreement with the company.

• · Cure period runs until the earlier of the next annual meeting of stockholders or November 3, 2027
• · Macleod's resignation takes effect upon closing of the polls for the election of directors at the November 3, 2026 Annual Meeting
• · Macleod will continue to serve as director, Audit Committee Chair, and member of the Compensation and Nominating/Corporate Governance Committees until her resignation
• · The Board intends to fill the resulting vacancy
• · Company is an emerging growth company incorporated in Delaware, file number 001-40932

30-10-2026

Banzai International filed an 8-K on October 30, 2026 disclosing a delisting notice (Item 3.01) and a same-day Certificate of Amendment increasing authorized capital to 850,000,000 shares, comprising 750,000,000 Class A common, 25,000,000 Class B common, and 75,000,000 preferred shares, all at $0.0001 par value. The charter amendment, approved by the requisite stockholders and signed by CEO Joseph Davy, took effect at 12:01 a.m. Eastern on October 30, 2026. The simultaneous delisting notice signals a negative listing-status development, while the capital increase may support restructuring or financing efforts.

• · Amendment adopted pursuant to Section 242 of the Delaware General Corporation Law
• · Amendment effective at 12:01 a.m. Eastern Time on October 30, 2026
• · Requisite stockholders approved the amendment
• · Filing includes Items 3.01 (delisting notice), 5.03 (charter amendment), 5.07 (stockholder vote), and 9.01 (exhibits)

30-10-2026

Actuate Therapeutics received a Nasdaq written notice on October 28, 2026, stating its common stock closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5450(a)(1). The notice has no immediate effect on listing, and the company has a 180-day compliance period until April 26, 2027 to regain compliance by maintaining a $1.00+ closing bid for at least 10 consecutive business days. This adds to a separate previously disclosed MVLS deficiency notice received July 15, 2026 (compliance deadline January 11, 2027), meaning the company faces two concurrent Nasdaq listing deficiencies with no assurance of cure.

• · Notice received October 28, 2026; 8-K filed October 30, 2026.
• · Common Stock par value is $0.000001 per share, trading on Nasdaq Global Market under symbol ACTU.
• · Separate MVLS deficiency notice received July 15, 2026, with compliance deadline of January 11, 2027.
• · Bid price notice does not affect the MVLS compliance period.
• · Second 180-day period requires meeting Nasdaq Capital Market market value of publicly-held shares and other initial listing standards (except bid price).
• · Company is an emerging growth company incorporated in Delaware, CIK 0001652935, file number 001-42139.
• · Failure to regain compliance across allotted periods could result in delisting.

30-10-2026

Neumora Therapeutics (NMRA) received a written notice from Nasdaq on October 26, 2026, indicating it is not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(a)(1). The company has 180 calendar days, until April 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days; it may seek additional time by transferring to the Nasdaq Capital Market, and has signaled it may pursue a reverse stock split. There is no assurance compliance will be regained, and failure could result in delisting, subject to appeal.

• · Notice received October 26, 2026; 8-K filed October 30, 2026
• · Compliance deadline is April 26, 2027 (180 calendar days)
• · To cure, closing bid must be at least $1.00 for a minimum of ten consecutive business days
• · If not compliant by April 26, 2027, company may apply to transfer to Nasdaq Capital Market, requiring market value of publicly held shares and other initial listing standards plus an application fee
• · Company would be entitled to appeal any delisting determination, but no assurance Nasdaq would grant continued listing
• · Company is considering a reverse stock split among options to resolve noncompliance

30-10-2026

Bridger Aerospace Group Holdings, Inc. (Nasdaq: BAER) received a Nasdaq deficiency letter on October 28, 2026, notifying the company that its common stock failed to maintain the $1.00 minimum bid price over the 30 consecutive business day period ended October 27, 2026, in violation of Nasdaq Listing Rule 5450(a)(1). The letter has no immediate effect on listing, and the company has until April 26, 2027 to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of ten consecutive business days. The company said it will monitor its bid price and may consider options including a reverse stock split, but cautioned there can be no assurance it will regain compliance.

• · Deficiency letter dated October 28, 2026, based on closing bid price for the 30 consecutive business day period ended October 27, 2026
• · Compliance deadline is April 26, 2027 (Nasdaq Listing Rule 5810(c)(3)(A))
• · If compliance is not regained, Staff will issue written delisting notice; company may appeal to a Nasdaq Hearings Panel, though no assurance of success
• · Common Stock continues to trade on The Nasdaq Global Market under symbol BAER with no immediate effect on listing
• · Company is an emerging growth company per the filing checkbox
• · Commission File Number 001-41603; IRS EIN 88-3599336; incorporated in Delaware; headquarters at 90 Aviation Lane, Belgrade, MT 59714

30-10-2026

Game Your Game Inc. filed an 8-K on October 30, 2026 disclosing the appointment of Veronica V. Montenegro to its Board of Directors effective October 28, 2026, with service through the 2027 annual stockholders' meeting. She will receive $50,000 annual cash compensation plus $27,500 in aggregate committee fees (Audit, Compensation, and as Governance Committee chair) and annual stock option grants with a grant date fair value of $77,500, fully vested with a 10-year term. The filing's header carries a delisting/failure-to-satisfy listing standard item flag, but the substantive body covers only the director appointment and related exhibits, with no financial results or delisting specifics disclosed.

• · Director term runs through the date of the next annual stockholders' meeting in 2027, with annual re-election thereafter
• · Stock options are fully vested on grant date, have a 10-year term, and exercise price equals fair market value on grant date
• · Cash and option compensation payable/issued in quarterly installments in arrears, prorated for the initial partial quarter
• · No arrangements or understandings between Ms. Montenegro and any other person regarding her selection; no family relationships or Item 404(a) related-party transactions
• · Company incorporated in Delaware (state of incorporation DE) though indemnification references Nevada law; fiscal year end December 31
• · Exhibits include Offer Letter dated October 28, 2026 (Ex 10.1), Form of Indemnification Agreement (Ex 10.2), and Form of 2026 Equity Incentive Plan Stock Option Agreement (Ex 10.3)
• · Filing signed by CEO Soumya Das on October 30, 2026; SEC File No. 001-43419